Physician

Navneet Virk, MD

According to 2025 Medicare claims, Navneet Virk, MD (NPI: 1275703076) practices hematology/oncology in the Sacramento-Roseville-Folsom, CA market, with the plurality of this provider's patient population coming from Sacramento, CA. This provider's primary affiliated billing organization is SIERRA HEMATOLOGY AND ONCOLOGY MEDICAL CENTERS (NPI: 1992796759; TIN: 680305843) and primary practice location at 95661-2847. Virk is affiliated with the Vivant Health ACO (ACO ID: A5068), participating under the MSSP model.

Virk's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 645 traditional Medicare patients, billed 163,169 HCPCS/CPT codes, and received $2,318,449 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,610 prescription claims across 232 beneficiaries totaling $4,134,871 in drug costs, led by Revlimid (Lenalidomide). DME data shows 34 claims. Open Payments data shows 22 records totaling $481. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $367,824 to $2,318,449. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,014,472 to $4,134,871. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	202	74,517	$367,824
2016	215	64,806	$674,048
2017	220	50,820	$825,080
2018	242	42,069	$781,067
2019	277	51,847	$639,957
2020	287	53,444	$671,437
2021	324	72,285	$877,020
2022	367	117,920	$1,142,954
2023	479	127,528	$1,571,197
2024	645	163,169	$2,318,449

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	105	776	$1,014,472
2016	133	967	$1,192,589
2017	144	1,295	$1,439,704
2018	163	1,288	$1,684,910
2019	157	1,317	$1,817,606
2020	167	1,394	$2,717,791
2021	184	1,505	$2,025,653
2022	205	1,481	$3,197,671
2023	201	1,507	$3,266,176
2024	232	1,610	$4,134,871

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	16	$730
2016	N/R	75	$32,847
2017	N/R	41	$12,850
2018	N/R	40	$3,941
2019	N/R	N/R	N/R
2020	N/R	12	$2,134
2021	N/R	34	$2,681
2022	N/R	33	$1,155
2023	N/R	31	$5,972
2024	N/R	34	$1,113

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	341	990	$103
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	324	463	$70
80053	Blood test, comprehensive group of blood chemicals	89	340	$10
36415	Insertion of needle into vein for collection of blood sample	227	802	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	219	1,009	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	69	1,827	$1,053,824
Verzenio	Abemaciclib	36	1,008	$551,016
Tagrisso	Osimertinib Mesylate	28	840	$439,765
Xtandi	Enzalutamide	33	990	$385,445
Tibsovo	Ivosidenib	12	360	$338,006

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	16	$774
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	18	$339

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	22	$481	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Navneet Virk, MD?

Tedicare shows public-source Medicare data for Navneet Virk, MD (NPI 1275703076), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Navneet Virk, MD have ACO affiliation data?

Navneet Virk, MD is shown with ACO affiliation data for Vivant Health ACO (MSSP, ACO ID A5068).

What billing organization is linked to Navneet Virk, MD?

Navneet Virk, MD is linked to SIERRA HEMATOLOGY AND ONCOLOGY MEDICAL CENTERS (billing NPI 1992796759) in the available physician profile data.

Does Navneet Virk, MD have Open Payments data?

Navneet Virk, MD has 22 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.